Cargando…

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro

Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40‐year‐old woman with type 2 diabetes mellitus who had been diagnosed with subcutaneous insulin resistan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Takahiro, Katayama, Akihiro, Sue, Mihiro, Kuribayashi, Remi, Tenta, Masafumi, Matsushita, Yuichi, Takeda, Masaya, Iseda, Izumi, Tani, Satomi, Hida, Kazuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902381/
https://www.ncbi.nlm.nih.gov/pubmed/34510782
http://dx.doi.org/10.1111/jdi.13667
_version_ 1784664586479206400
author Ishii, Takahiro
Katayama, Akihiro
Sue, Mihiro
Kuribayashi, Remi
Tenta, Masafumi
Matsushita, Yuichi
Takeda, Masaya
Iseda, Izumi
Tani, Satomi
Hida, Kazuyuki
author_facet Ishii, Takahiro
Katayama, Akihiro
Sue, Mihiro
Kuribayashi, Remi
Tenta, Masafumi
Matsushita, Yuichi
Takeda, Masaya
Iseda, Izumi
Tani, Satomi
Hida, Kazuyuki
author_sort Ishii, Takahiro
collection PubMed
description Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40‐year‐old woman with type 2 diabetes mellitus who had been diagnosed with subcutaneous insulin resistance syndrome since the age of 29 years, and had been persistently treated with continuous subcutaneous insulin infusion using a mixture of insulin lispro and heparin. The patient was switched from insulin lispro plus heparin to ultra‐rapid insulin lispro; given that it contains treprostinil and citrate, it is expected to have similar effects as heparin, and shows similar glucose‐lowering effects and insulin absorption. Our results suggest that treatment with ultra‐rapid insulin lispro is effective for subcutaneous insulin resistance syndrome.
format Online
Article
Text
id pubmed-8902381
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89023812022-03-11 Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro Ishii, Takahiro Katayama, Akihiro Sue, Mihiro Kuribayashi, Remi Tenta, Masafumi Matsushita, Yuichi Takeda, Masaya Iseda, Izumi Tani, Satomi Hida, Kazuyuki J Diabetes Investig Articles Subcutaneous insulin resistance syndrome is a rare condition that causes difficulty in glycemic control due to severe resistance to subcutaneous insulin injections. We herein present a case of a 40‐year‐old woman with type 2 diabetes mellitus who had been diagnosed with subcutaneous insulin resistance syndrome since the age of 29 years, and had been persistently treated with continuous subcutaneous insulin infusion using a mixture of insulin lispro and heparin. The patient was switched from insulin lispro plus heparin to ultra‐rapid insulin lispro; given that it contains treprostinil and citrate, it is expected to have similar effects as heparin, and shows similar glucose‐lowering effects and insulin absorption. Our results suggest that treatment with ultra‐rapid insulin lispro is effective for subcutaneous insulin resistance syndrome. John Wiley and Sons Inc. 2021-09-27 2022-03 /pmc/articles/PMC8902381/ /pubmed/34510782 http://dx.doi.org/10.1111/jdi.13667 Text en © 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Ishii, Takahiro
Katayama, Akihiro
Sue, Mihiro
Kuribayashi, Remi
Tenta, Masafumi
Matsushita, Yuichi
Takeda, Masaya
Iseda, Izumi
Tani, Satomi
Hida, Kazuyuki
Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title_full Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title_fullStr Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title_full_unstemmed Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title_short Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
title_sort case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902381/
https://www.ncbi.nlm.nih.gov/pubmed/34510782
http://dx.doi.org/10.1111/jdi.13667
work_keys_str_mv AT ishiitakahiro caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT katayamaakihiro caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT suemihiro caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT kuribayashiremi caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT tentamasafumi caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT matsushitayuichi caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT takedamasaya caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT isedaizumi caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT tanisatomi caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro
AT hidakazuyuki caseofsubcutaneousinsulinresistancesyndrometreatedwithultrarapidinsulinlispro